Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 111

1.

Male exposure to bisphenol A (BPA) and semen quality in the Home Observation of Periconceptional Exposures (HOPE) cohort.

Pollard SH, Cox KJ, Blackburn BE, Wilkins DG, Carrell DT, Stanford JB, Porucznik CA.

Reprod Toxicol. 2019 Aug 21. pii: S0890-6238(19)30093-0. doi: 10.1016/j.reprotox.2019.08.014. [Epub ahead of print]

PMID:
31445078
2.

The Relationship Between Circulating Acetaminophen-Protein Adduct Concentrations and Alanine Aminotransferase Activities in Patients With and Without Acetaminophen Overdose and Toxicity.

Curry SC, Padilla-Jones A, Ruha AM, O'Connor AD, Kang AM, Wilkins DG, Jaeschke H, Wilhelms K, Gerkin RD; Acetaminophen Adduct Study Group.

J Med Toxicol. 2019 Jul;15(3):143-155. doi: 10.1007/s13181-019-00705-2. Epub 2019 Apr 12.

PMID:
30980348
3.

Development and validation of an assay for quantifying budesonide in dried blood spots collected from extremely low gestational age neonates.

Rower JE, Anderson DJ, Sherwin CM, Reilly CA, Ballard PL, McEvoy CT, Wilkins DG.

J Pharm Biomed Anal. 2019 Apr 15;167:7-14. doi: 10.1016/j.jpba.2019.01.048. Epub 2019 Jan 29.

PMID:
30738243
4.

Polymorphic Expression of UGT1A9 is Associated with Variable Acetaminophen Glucuronidation in Neonates: A Population Pharmacokinetic and Pharmacogenetic Study.

Linakis MW, Cook SF, Kumar SS, Liu X, Wilkins DG, Gaedigk R, Gaedigk A, Sherwin CMT, van den Anker JN.

Clin Pharmacokinet. 2018 Oct;57(10):1325-1336. doi: 10.1007/s40262-018-0634-9.

PMID:
29654492
5.

Population pharmacokinetic model of transdermal nicotine delivered from a matrix-type patch.

Linakis MW, Rower JE, Roberts JK, Miller EI, Wilkins DG, Sherwin CMT.

Br J Clin Pharmacol. 2017 Dec;83(12):2709-2717. doi: 10.1111/bcp.13393. Epub 2017 Sep 6.

6.

Neonatal Maturation of Paracetamol (Acetaminophen) Glucuronidation, Sulfation, and Oxidation Based on a Parent-Metabolite Population Pharmacokinetic Model.

Cook SF, Stockmann C, Samiee-Zafarghandy S, King AD, Deutsch N, Williams EF, Wilkins DG, Sherwin CM, van den Anker JN.

Clin Pharmacokinet. 2016 Nov;55(11):1395-1411.

7.

Detection of Acetaminophen-Protein Adducts in Decedents with Suspected Opioid-Acetaminophen Combination Product Overdose.

Thomas KC, Wilkins DG, Curry SC, Grey TC, Andrenyak DM, McGill LD, Rollins DE.

J Forensic Sci. 2016 Sep;61(5):1301-6. doi: 10.1111/1556-4029.13169. Epub 2016 Aug 1.

8.

The Home Observation of Periconceptional Exposures (HOPE) study, a prospective cohort: aims, design, recruitment and compliance.

Porucznik CA, Cox KJ, Schliep KC, Wilkins DG, Stanford JB.

Environ Health. 2016 Jun 8;15(1):67. doi: 10.1186/s12940-016-0153-9.

9.
10.

A comparative evaluation of self-report and biological measures of cigarette use in nondaily smokers.

Wray JM, Gass JC, Miller EI, Wilkins DG, Rollins DE, Tiffany ST.

Psychol Assess. 2016 Sep;28(9):1043-50. doi: 10.1037/pas0000227. Epub 2015 Oct 19.

11.

Chronic Nicotine Exposure Attenuates Methamphetamine-Induced Dopaminergic Deficits.

Vieira-Brock PL, McFadden LM, Nielsen SM, Ellis JD, Walters ET, Stout KA, McIntosh JM, Wilkins DG, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2015 Dec;355(3):463-72. doi: 10.1124/jpet.114.221945. Epub 2015 Sep 21.

12.

Exposure Classification and Temporal Variability in Urinary Bisphenol A Concentrations among Couples in Utah--The HOPE Study.

Cox KJ, Porucznik CA, Anderson DJ, Brozek EM, Szczotka KM, Bailey NM, Wilkins DG, Stanford JB.

Environ Health Perspect. 2016 Apr;124(4):498-506. doi: 10.1289/ehp.1509752. Epub 2015 Sep 15.

13.

A Population Pharmacokinetic Analysis of Dextroamphetamine in the Plasma and Hair of Healthy Adults.

Roberts JK, Cook SF, Stockmann C, Rollins DE, Wilkins DG, Sherwin CM.

Clin Drug Investig. 2015 Oct;35(10):633-43. doi: 10.1007/s40261-015-0323-5.

14.

Population Pharmacokinetics of Intravenous Paracetamol (Acetaminophen) in Preterm and Term Neonates: Model Development and External Evaluation.

Cook SF, Roberts JK, Samiee-Zafarghandy S, Stockmann C, King AD, Deutsch N, Williams EF, Allegaert K, Wilkins DG, Sherwin CM, van den Anker JN.

Clin Pharmacokinet. 2016 Jan;55(1):107-19. doi: 10.1007/s40262-015-0301-3.

15.

A Preliminary Study of Biomonitoring for Bisphenol-A in Human Sweat.

Porucznik CA, Cox KJ, Wilkins DG, Anderson DJ, Bailey NM, Szczotka KM, Stanford JB.

J Anal Toxicol. 2015 Sep;39(7):562-6. doi: 10.1093/jat/bkv055. Epub 2015 May 25.

PMID:
26013102
16.

Confirming the Causative Role of Acetaminophen in Indeterminate Acute Liver Failure Using Acetaminophen-Cysteine Adducts.

Frey SM, Wiegand TJ, Green JL, Heard KJ, Wilkins DG, Gorodetsky RM, Dart RC.

J Med Toxicol. 2015 Jun;11(2):218-22. doi: 10.1007/s13181-015-0476-x.

17.

Time course of acetaminophen-protein adducts and acetaminophen metabolites in circulation of overdose patients and in HepaRG cells.

Xie Y, McGill MR, Cook SF, Sharpe MR, Winefield RD, Wilkins DG, Rollins DE, Jaeschke H.

Xenobiotica. 2015;45(10):921-9. doi: 10.3109/00498254.2015.1026426. Epub 2015 Apr 14.

18.

Quantification of a biomarker of acetaminophen protein adducts in human serum by high-performance liquid chromatography-electrospray ionization-tandem mass spectrometry: clinical and animal model applications.

Cook SF, King AD, Chang Y, Murray GJ, Norris HR, Dart RC, Green JL, Curry SC, Rollins DE, Wilkins DG.

J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Mar 15;985:131-41. doi: 10.1016/j.jchromb.2015.01.028. Epub 2015 Jan 24.

PMID:
25681644
19.

Prolonged Acetaminophen-Protein Adduct Elimination During Renal Failure, Lack of Adduct Removal by Hemodiafiltration, and Urinary Adduct Concentrations After Acetaminophen Overdose.

Curry SC, Padilla-Jones A, O'Connor AD, Ruha AM, Bikin DS, Wilkins DG, Rollins DE, Slawson MH, Gerkin RD; Acetaminophen Adduct Study Group.

J Med Toxicol. 2015 Jun;11(2):169-78. doi: 10.1007/s13181-014-0431-2.

20.

Assessing orally bioavailable commercial silver nanoparticle product on human cytochrome P450 enzyme activity.

Munger MA, Hadlock G, Stoddard G, Slawson MH, Wilkins DG, Cox N, Rollins D.

Nanotoxicology. 2015 May;9(4):474-81. doi: 10.3109/17435390.2014.948092. Epub 2014 Aug 19.

PMID:
25137296
21.

Biomonitoring method for bisphenol A in human urine by ultra-high-performance liquid chromatography-tandem mass spectrometry.

Anderson DJ, Brozek EM, Cox KJ, Porucznik CA, Wilkins DG.

J Chromatogr B Analyt Technol Biomed Life Sci. 2014 Mar 15;953-954:53-61. doi: 10.1016/j.jchromb.2014.01.039. Epub 2014 Feb 2.

22.

Age-related differences in the disposition of nicotine and metabolites in rat brain and plasma.

Vieira-Brock PL, Andrenyak DM, Nielsen SM, Fleckenstein AE, Wilkins DG.

Nicotine Tob Res. 2013 Nov;15(11):1839-48. doi: 10.1093/ntr/ntt067. Epub 2013 Jun 4.

23.

Plasma and liver acetaminophen-protein adduct levels in mice after acetaminophen treatment: dose-response, mechanisms, and clinical implications.

McGill MR, Lebofsky M, Norris HR, Slawson MH, Bajt ML, Xie Y, Williams CD, Wilkins DG, Rollins DE, Jaeschke H.

Toxicol Appl Pharmacol. 2013 Jun 15;269(3):240-9. doi: 10.1016/j.taap.2013.03.026. Epub 2013 Apr 6.

24.

Methadone and metabolites in hair of methadone-assisted pregnant women and their infants.

Himes SK, Goodwin RS, Rock CM, Jones HE, Johnson RE, Wilkins DG, Huestis MA.

Ther Drug Monit. 2012 Jun;34(3):337-44. doi: 10.1097/FTD.0b013e3182512b26.

25.

Methamphetamine self-administration acutely decreases monoaminergic transporter function.

McFadden LM, Stout KA, Vieira-Brock PL, Allen SC, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE.

Synapse. 2012 Mar;66(3):240-5. doi: 10.1002/syn.21506. Epub 2011 Dec 13.

26.

Methamphetamine self-administration causes persistent striatal dopaminergic alterations and mitigates the deficits caused by a subsequent methamphetamine exposure.

McFadden LM, Hadlock GC, Allen SC, Vieira-Brock PL, Stout KA, Ellis JD, Hoonakker AJ, Andrenyak DM, Nielsen SM, Wilkins DG, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2012 Feb;340(2):295-303. doi: 10.1124/jpet.111.188433. Epub 2011 Oct 27.

27.

Simultaneous quantification of nicotine and metabolites in rat brain by liquid chromatography-tandem mass spectrometry.

Vieira-Brock PL, Miller EI, Nielsen SM, Fleckenstein AE, Wilkins DG.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Nov 15;879(30):3465-74. doi: 10.1016/j.jchromb.2011.09.026. Epub 2011 Sep 18.

28.

4-Methylmethcathinone (mephedrone): neuropharmacological effects of a designer stimulant of abuse.

Hadlock GC, Webb KM, McFadden LM, Chu PW, Ellis JD, Allen SC, Andrenyak DM, Vieira-Brock PL, German CL, Conrad KM, Hoonakker AJ, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2011 Nov;339(2):530-6. doi: 10.1124/jpet.111.184119. Epub 2011 Aug 2.

30.

Methamphetamine treatment during development attenuates the dopaminergic deficits caused by subsequent high-dose methamphetamine administration.

McFadden LM, Hoonakker AJ, Vieira-Brock PL, Stout KA, Sawada NM, Ellis JD, Allen SC, Walters ET, Nielsen SM, Gibb JW, Alburges ME, Wilkins DG, Hanson GR, Fleckenstein AE.

Synapse. 2011 Aug;65(8):771-7. doi: 10.1002/syn.20902. Epub 2011 Mar 21.

31.

Identification and quantification of nicotine biomarkers in human oral fluid from individuals receiving low-dose transdermal nicotine: a preliminary study.

Miller EI, Norris HR, Rollins DE, Tiffany ST, Moore CM, Vincent MJ, Agrawal A, Wilkins DG.

J Anal Toxicol. 2010 Sep;34(7):357-66.

PMID:
20822672
32.

A novel validated procedure for the determination of nicotine, eight nicotine metabolites and two minor tobacco alkaloids in human plasma or urine by solid-phase extraction coupled with liquid chromatography-electrospray ionization-tandem mass spectrometry.

Miller EI, Norris HR, Rollins DE, Tiffany ST, Wilkins DG.

J Chromatogr B Analyt Technol Biomed Life Sci. 2010 Mar 15;878(9-10):725-37. doi: 10.1016/j.jchromb.2009.12.018. Epub 2009 Dec 22.

33.

Mechanisms underlying methamphetamine-induced dopamine transporter complex formation.

Hadlock GC, Baucum AJ 2nd, King JL, Horner KA, Cook GA, Gibb JW, Wilkins DG, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2009 Apr;329(1):169-74. doi: 10.1124/jpet.108.145631. Epub 2009 Jan 13.

34.

Buprenorphine and norbuprenorphine in hair of pregnant women and their infants after controlled buprenorphine administration.

Goodwin RS, Wilkins DG, Averin O, Choo RE, Schroeder JR, Jasinski DR, Johnson RE, Jones HE, Huestis MA.

Clin Chem. 2007 Dec;53(12):2136-43. Epub 2007 Oct 5.

35.

Misclassification of maternal smoking status and its effects on an epidemiologic study of pregnancy outcomes.

England LJ, Grauman A, Qian C, Wilkins DG, Schisterman EF, Yu KF, Levine RJ.

Nicotine Tob Res. 2007 Oct;9(10):1005-13.

PMID:
17852766
36.

Persistence of tolerance to methamphetamine-induced monoamine deficits.

Danaceau JP, Deering CE, Day JE, Smeal SJ, Johnson-Davis KL, Fleckenstein AE, Wilkins DG.

Eur J Pharmacol. 2007 Mar 15;559(1):46-54. Epub 2006 Dec 1.

PMID:
17239369
37.

Age-dependent effects of methamphetamine on VMAT-2.

Rau KS, Truong JG, Wilkins DG, Fleckenstein AE, Hanson GR.

Ann N Y Acad Sci. 2006 Aug;1074:154-9.

PMID:
17105913
38.

Withdrawal from lorazepam in critically ill children.

Dominguez KD, Crowley MR, Coleman DM, Katz RW, Wilkins DG, Kelly HW.

Ann Pharmacother. 2006 Jun;40(6):1035-9. Epub 2006 May 23.

PMID:
16720707
39.

Bupropion increases striatal vesicular monoamine transport.

Rau KS, Birdsall E, Hanson JE, Johnson-Davis KL, Carroll FI, Wilkins DG, Gibb JW, Hanson GR, Fleckenstein AE.

Neuropharmacology. 2005 Nov;49(6):820-30. Epub 2005 Jul 7.

PMID:
16005476
40.

Age-dependent methamphetamine-induced alterations in vesicular monoamine transporter-2 function: implications for neurotoxicity.

Truong JG, Wilkins DG, Baudys J, Crouch DJ, Johnson-Davis KL, Gibb JW, Hanson GR, Fleckenstein AE.

J Pharmacol Exp Ther. 2005 Sep;314(3):1087-92. Epub 2005 May 18.

PMID:
15901804
41.

Alterations in vesicular dopamine uptake contribute to tolerance to the neurotoxic effects of methamphetamine.

Johnson-Davis KL, Truong JG, Fleckenstein AE, Wilkins DG.

J Pharmacol Exp Ther. 2004 May;309(2):578-86. Epub 2004 Jan 27.

PMID:
14747615
42.

The effect of hair color on the incorporation of codeine into human hair.

Rollins DE, Wilkins DG, Krueger GG, Augsburger MP, Mizuno A, O'Neal C, Borges CR, Slawson MH.

J Anal Toxicol. 2003 Nov-Dec;27(8):545-51.

PMID:
14670132
43.

The role of hyperthermia and metabolism as mechanisms of tolerance to methamphetamine neurotoxicity.

Johnson-Davis KL, Fleckenstein AE, Wilkins DG.

Eur J Pharmacol. 2003 Dec 15;482(1-3):151-4.

PMID:
14660016
44.

Opiate recidivism in a drug-treatment program: comparison of hair and urine data.

Charles BK, Day JE, Rollins DE, Andrenyak D, Ling W, Wilkins DG.

J Anal Toxicol. 2003 Oct;27(7):412-28.

PMID:
14606994
45.

Ofloxacin as a reference marker in hair of various colors.

Wilkins DG, Mizuno A, Borges CR, Slawson MH, Rollins DE.

J Anal Toxicol. 2003 Apr;27(3):149-55.

PMID:
12731656
46.

Cocaine, benzoylecgonine, amphetamine, and N-acetylamphetamine binding to melanin subtypes.

Borges CR, Roberts JC, Wilkins DG, Rollins DE.

J Anal Toxicol. 2003 Apr;27(3):125-34.

PMID:
12731652
47.

Influx and efflux of amphetamine and N-acetylamphetamine in keratinocytes, pigmented melanocytes, and nonpigmented melanocytes.

Borges CR, Martin SD, Meyer LJ, Wilkins DG, Rollins DE.

J Pharm Sci. 2002 Jun;91(6):1523-35.

PMID:
12115851
48.

Indicators of cocaine exposure and preterm birth.

Savitz DA, Henderson L, Dole N, Herring A, Wilkins DG, Rollins D, Thorp JM Jr.

Obstet Gynecol. 2002 Mar;99(3):458-65.

PMID:
11864674
49.

Tolerance to the neurotoxic effects of methamphetamine in young rats.

Riddle EL, Kokoshka JM, Wilkins DG, Hanson GR, Fleckenstein AE.

Eur J Pharmacol. 2002 Jan 25;435(2-3):181-5.

PMID:
11821024
50.

Maternal serum caffeine metabolites and small-for-gestational age birth.

Klebanoff MA, Levine RJ, Clemens JD, Wilkins DG.

Am J Epidemiol. 2002 Jan 1;155(1):32-7.

PMID:
11772782

Supplemental Content

Loading ...
Support Center